Posts Tagged ‘vaccines’

EPA Study: Autism Boom Began in 1988, Environmental Factors Are Assumed

EPA Study: Autism Boom Began in 1988, Environmental Factors Are Assumed

Courtesy of David Kirby at The Huffington Post 

If it seems like most of the people you know with autism are 22 or younger, that’s because most people diagnosed with autism were born after 1987. A recent US EPA study has found a distinct "changepoint" year – or spike – in autism in California and elsewhere and concludes that it would be "prudent to assume that at least some portion of this increase is real and results from environmental factors."

"In the Danish, California, and worldwide data sets, we found that an increase in autism disorder cumulative incidence began about (the birth cohort years) 1988-1989," wrote the authors Michael E. Mc Donald and John F. Paul, of the EPA’s National Health and Environmental Effects Research Laboratory.

"Although the debate about the nature of increasing autism continues," they added, "the potential for this increase to be real and involve exogenous (external) environmental stressors exists."

But it was the distinct timing in the increase of autism – the birth of an epidemic, as many believe – that was most notable, and which "may help in screening for potential candidate environmental stressors."

"The calculated year was determined to be significant," the EPA scientists said. The rate of increase before 1988 "was significantly different" than the rate after that year (the "postchangepoint," in epidemiology parlance). In California, the rate spiked from 5.7-per-10,000 before the changepoint, to 20.8-per 10,000 in its wake, and the worldwide dataset showed a similar jump (from 6.0 to 24.2). In Denmark, the rise was even more dramatic, though total incidence was only a fraction of that in the US: from 0.6 to 6.6.

(A study in Japan from 1988-1996 showed continuously increasing autism rates, but no calculable changepoint year – please see the full report for a discussion on study limitations).

So why would rates more than triple in California kids born before and after 1988? Is…
continue reading


Tags: , , , , , , , , , ,




Double-Edged Sword: Swine Flu and Vaccines

By guest author Terry Doherty and Ilene, your editor

Terry Doherty is the Research Program Coordinator in the Depts of Biomedical Sciences and Academic Affairs at Cedar Sinai in Los Angeles, California.

Double-Edged Sword: Swine Flu and Vaccines

There’s plenty that is unknown about the swine flu and the swine flu vaccine.  If searches on the internet are any indication, deciding whether or not to be vaccinated may be a tough, emotionally charged decision for many people.  So how – without having the background to write a swine flu grant proposal, conduct the research, and get the thing published in the New England Journal of Medicine – do we decide whether or not to get a swine flu shot?  

One way is to attempt to evaluate and weigh the risks of the vaccine against the risks of the flu.  That is how I approach the subject, but it’s easier said than done.  As is often the case with medical interventions, the risks are not fully known. And even if we could carefully assess the risks, our underlying assumptions may be wrong.  Percent risks are averages collected by studying large populations.  We may not be one of the statistical average.  Then there are the gaps in the available data, and own biases and belief systems.  Our view of the world affects our analysis and often we are not even aware of how large of an effect those biases may play.   

In Vaccine War: Autism, Flu and Science, TIME, Maia Szalavitz discusses how emotion and biases play a large part in our risk-benefit assessments:

Just in time for the national roll-out of the new H1N1 flu vaccine, Wired Magazine and the Atlantic have weighed in on the ongoing vaccine war: Wired has a profile of Paul Offit, a vaccine researcher and pediatrician who has consistently spoken out in favor of vaccination and pointed to the lack of evidence linking vaccines and autism; the Atlantic checks in with a piece questioning the science suggesting that flu vaccines and antiviral drugs prevent people from dying.

Both articles have elicited heated debate all over the Web: Amy Wallace, who wrote Wired’s piece, excerpted below, has received vitriolic criticism and attacks from vaccine opponents, setting records for page views…

This debate over vaccination doesn’t seem likely to end any time soon. For critics, vaccines…
continue reading


Tags: , , , , , , , , , , , ,




In Germany, A Better H1N1 Vaccine For Politicians?

For additional reading on the swine flu vaccine situation in Germany, see the article at the end translated by my friend Bob, in red.  Thank you Bob. - Ilene

In Germany, A Better H1N1 Vaccine For Politicians?

vaccinesBy Tristana Moore / Berlin, Courtesy of TIME

Critics are calling it a two-tier health system — one for the politically well-connected, another for the hoi polloi. As Germany launched its mass vaccination program against the H1N1 flu virus on Monday, the government found itself fending off accusations of favoritism by offering one vaccine believed to have fewer side effects to civil servants, politicians and soldiers, and another potentially riskier vaccine to everyone else. The government had hoped that Germans would rush to health clinics to receive vaccinations against the rapidly spreading disease, but the rising anger over the different doses may now cause many people to shy away.

Amid growing fears over a possible global flu pandemic, the German government prepared for its mass vaccination campaign earlier this year by ordering 50 million doses of the Pandemrix vaccine, which would be enough for a double dose for 25 million people, around a third of the population. The vaccine, manufactured by GlaxoSmithKline, contains an immune-enhancing chemical compound, known as an adjuvant, whose side effects are not yet entirely known. Then, after a report was leaked to the German media last week, the Interior Ministry confirmed that it had ordered a different vaccine, Celvapan, for government officials and the military. Celvapan, which is made by the U.S. pharmaceutical giant Baxter, does not contain an adjuvant and is believed to have fewer side effects than Pandemrix.

Anger at the news was widespread in Germany. "If mass vaccination is considered to be necessary, then everyone should be treated the same way," says Birgitt Bender, the health spokeswoman for the Green Party. Ulrike Mascher, head of the VdK social welfare association, said giving government officials a different vaccine from the rest of the population sent the "wrong signal" and gave many people "the impression that they are second-class patients." A story on the front page of the mass-circulation Bild newspaper accused the government of giving "second-class medicine" to regular Germans.

Doctors and medical experts are divided over the safety of Pandemrix. While some say it’s the best vaccine available, others have serious misgivings about it. "The Pandemrix vaccine can’t be recommended…
continue reading


Tags: , , , , ,




New Study: Hepatitis B Vaccine Triples the Risk of Autism in Infant Boys

Weekend off-topic reading.  I found this fascinating. - Ilene  

New Study: Hepatitis B Vaccine Triples the Risk of Autism in Infant Boys

Courtesy of David Kirby writing at the Huffington Post

"The science is largely complete. Ten epidemiological studies have shown MMR vaccine doesn’t cause autism; six have shown thimerosal doesn’t cause autism."-- Dr. Paul Offit, "Autism’s False Prophets"

"16 studies have shown no causal association between vaccines and autism, and these studies carry weight in the scientific industry."-- Dr. Nancy Snyderman, NBC Today Show Medical Editor

Conventional wisdom holds that the autism-vaccine question has been "asked and answered," and that at least 16 large, well-constructed epidemiological studies have thoroughly addressed and debunked any hypothesis that childhood vaccination is in any way associated with an increased risk for autism spectrum disorders.

But there are several critical flaws in such an oversimplified generalization, and they are rarely given close examination by public health experts or members of the media.

To begin with, it is unscientific and perilously misleading for anyone to assert that "vaccines and autism" have been studied and that no link has been found. That’s because the 16 or so studies constantly cited by critics of the hypothesis have examined just one vaccine and one vaccine ingredient.

And, the population studies themselves have had critical design flaws and limitations.

The current US childhood immunization schedule calls for 28 injections with 11 different vaccines against 15 different diseases by two years of age. Of those 11 vaccines, only the Measles-Mumps-Rubella (MMR) shot has been studied in association with autism, (although a CDC study of an MMR-plus-chickenpox vaccine did show that the risk for febrile seizures in infants was doubled.) Meanwhile, those 11 vaccines contain scores of ingredients, only one of which, thimerosal, has ever been tested in association with autism.

It is illogical to exonerate all vaccines, all vaccine ingredients, and the total US vaccine program as a whole, based solely on a handful of epidemiological studies of just one vaccine and one vaccine ingredient. It is akin to claiming that every form of animal protein is beneficial to people, when all you have studied is fish.

Now, a new study has shown that giving Hepatitis B vaccine to newborn baby boys may triple the risk of developing an autism spectrum disorder.

An abstract of the study was published in the September, 2009…
continue reading


Tags: , , , , , , ,




Swine Flu Vaccine: Watching For Side Effects

The decision regarding whether or not to get vaccinated for swine flu, or have your kids vaccinated, may be easy for some, but is not for others. It depends on how you perceive and value the risks. As is often the case with medical interventions, the risks are not fully known or understood. Even if you’re lucky enough to believe you’ve obtained valid risk percentages to compare, you cannot truly know whether your assumptions accurately reflect reality. And your numbers certainly don’t factor in the unknown.

So as the swine flu vaccine program gets underway, several government-sponsored projects will attempt to determine how safe the vaccine really is. We have a rather unique opportunity to learn a lot more while serving as subjects in this grand experiment.

Go ahead, leave comments and share your thoughts… – Ilene

Swine Flu Vaccine: Watching For Side Effects

(WASHINGTON) — More than 3,000 people a day have a heart attack. If you’re one of them the day after your swine flu shot, will you worry the vaccine was to blame and not the more likely culprit, all those burgers and fries?

The government is starting an unprecedented system to track possible side effects as mass flu vaccinations begin next month. The idea is to detect any rare but real problems quickly, and explain the inevitable coincidences that are sure to cause some false alarms.

"Every day, bad things happen to people. When you vaccinate a lot of people in a short period of time, some of those things are going to happen to some people by chance alone," said Dr. Daniel Salmon, a vaccine safety specialist at the Department of Health and Human Services.

Health authorities hope to vaccinate well over half the population in just a few months against swine flu, which doctors call the 2009 H1N1 strain. That would be a feat. No more than 100 million Americans usually get vaccinated against regular winter flu, and never in such a short period.

How many will race for the vaccine depends partly on confidence in its safety. The last mass inoculations against a different swine flu, in 1976, were marred by reports of a rare paralyzing condition, Guillain-Barre syndrome.

"The recurring question is, ‘How…
continue reading


Tags: , , , , , , ,




 
 
 

Phil's Favorites

Overpriced tech IPOs sell grand visions but aren't worth their valuations

 

Overpriced tech IPOs sell grand visions but aren't worth their valuations

rblfmr / Shutterstock.com

Courtesy of John Colley, Warwick Business School, University of Warwick

The year of the tech IPO is 2019. Uber went public on May 10 with a US$82.4 billion valuation. Fellow ride-sharing app Lyft floated in March with a U$24 billion valuation and Pinterest had a US$10 billion IPO in April...



more from Ilene

Zero Hedge

The Boycott Begins: Chinese Company Orders Employees To "Stop Using American Products, Eating At KFC"

Courtesy of ZeroHedge. View original post here.

In a harbinger of what's to come as the US-China trade war gets worse by the day, a Chinese company has told all of its employees to boycott American products and halt international travels to the U.S., reported The Epoch Times.

Jinggang Motor Vehicle Inspection Station notif...



more from Tyler

Kimble Charting Solutions

Emerging Markets About To Submerge If 3-Year Support Breaks?

Courtesy of Chris Kimble.

Are Emerging Markets about to “Submerge” and head a good deal lower? What they do at (3) will go a long way in answering this question!

Emerging Markets ETF (EEM) has been lagging the broad market for the past 15-months. They hit their 50% retracement level of the last year’s highs and lows and falling resistance at (2) recently. The weakness of last has EEM trading below its 200-MA line.

EEM has spent the majority of the past 3-years inside of rising channel (1), which reflects that this trend remains up. The weakness of late has it testing the bo...



more from Kimble C.S.

Insider Scoop

Amgen To Buy Danish Collaborator Nuevolution For $167M

Courtesy of Benzinga.

Amgen, Inc. (NASDAQ: AMGN) took a logical step forward in buying a preclinical biotech it has been collaborating with since 2016. 

What Happened

Amgen announced Wednesday an agreement to buy Copenhagen-based Nuevolution for $167 million.

Th...



http://www.insidercow.com/ more from Insider

Chart School

Weekly Market Recap May 18, 2019

Courtesy of Blain.

China – U.S. trade talk continued to dominate the week.   A heavy selloff Monday was followed by 3 up days, with Friday moderately down.

On Monday, Chinese officials announced retaliatory tariffs against the U.S., hitting $60 billion in annual exports to China with new or expanded duties that could reach 25%.

Then on Wednesday:

The Trump administration plans to delay a decision on instituting new tariffs on car and auto part imports for up to six months, according to media reports.

...

more from Chart School

Digital Currencies

Cryptocurrencies are finally going mainstream - the battle is on to bring them under global control

 

Cryptocurrencies are finally going mainstream – the battle is on to bring them under global control

The high seas are getting lower. dianemeise

Courtesy of Iwa Salami, University of East London

The 21st-century revolutionaries who have dominated cryptocurrencies are having to move over. Mainstream financial institutions are adopting these assets and the blockchain technology that enables them, in what ...



more from Bitcoin

Biotech

DNA as you've never seen it before, thanks to a new nanotechnology imaging method

Reminder: We are available to chat with Members, comments are found below each post.

 

DNA as you've never seen it before, thanks to a new nanotechnology imaging method

A map of DNA with the double helix colored blue, the landmarks in green, and the start points for copying the molecule in red. David Gilbert/Kyle Klein, CC BY-ND

Courtesy of David M. Gilbert, Florida State University

...



more from Biotech

ValueWalk

More Examples Of "Typical Tesla "wise-guy scamminess"

By Jacob Wolinsky. Originally published at ValueWalk.

Stanphyl Capital’s letter to investors for the month of March 2019.

rawpixel / Pixabay

Friends and Fellow Investors:

For March 2019 the fund was up approximately 5.5% net of all fees and expenses. By way of comparison, the S&P 500 was up approximately 1.9% while the Russell 2000 was down approximately 2.1%. Year-to-date 2019 the fund is up approximately 12.8% while the S&P 500 is up approximately 13.6% and the ...



more from ValueWalk

Members' Corner

Despacito - How to Make Money the Old-Fashioned Way - SLOWLY!

Are you ready to retire?  

For most people, the purpose of investing is to build up enough wealth to allow you to retire.  In general, that's usually enough money to reliably generate a year's worth of your average income, each year into your retirement so that that, plus you Social Security, should be enough to pay your bills without having to draw down on your principle.

Unfortunately, as the last decade has shown us, we can't count on bonds to pay us more than 3% and the average return from the stock market over the past 20 years has been erratic - to say the least - with 4 negative years (2000, 2001, 2002 and 2008) and 14 positives, though mostly in the 10% range on the positives.  A string of losses like we had from 2000-02 could easily wipe out a decades worth of gains.

Still, the stock market has been better over the last 10 (7%) an...



more from Our Members

Mapping The Market

It's Not Capitalism, it's Crony Capitalism

A good start from :

It's Not Capitalism, it's Crony Capitalism

Excerpt:

The threat to America is this: we have abandoned our core philosophy. Our first principle of this nation as a meritocracy, a free-market economy, where competition drives economic decision-making. In its place, we have allowed a malignancy to fester, a virulent pus-filled bastardized form of economics so corrosive in nature, so dangerously pestilent, that it presents an extinction-level threat to America – both the actual nation and the “idea” of America.

This all-encompassing mutant corruption saps men’s souls, crushes opportunities, and destroys economic mobility. Its a Smash & Grab system of ill-gotten re...



more from M.T.M.

OpTrader

Swing trading portfolio - week of September 11th, 2017

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Promotions

Free eBook - "My Top Strategies for 2017"

 

 

Here's a free ebook for you to check out! 

Phil has a chapter in a newly-released eBook that we think you’ll enjoy.

In My Top Strategies for 2017, Phil's chapter is Secret Santa’s Inflation Hedges for 2017.

This chapter isn’t about risk or leverage. Phil present a few smart, practical ideas you can use as a hedge against inflation as well as hedging strategies designed to assist you in staying ahead of the markets.

Some other great content in this free eBook includes:

 

·       How 2017 Will Affect Oil, the US Dollar and the European Union

...

more from Promotions





About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>